Alunbrig Alternatives Compared
| Alunbrig | Nivolumab | Retevmo |
|
|---|
| Alunbrig (brigatinib) | Nivolumab | Retevmo (selpercatinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Non-Small Cell Lung Cancer. Alunbrig may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Esophageal Carcinoma, Colorectal Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma - Metastatic, Non-Small... View more |
Prescription only
Prescribed for Non-Small Cell Lung Cancer, Solid Tumors, Thyroid Cancer. Retevmo may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Alunbrig (brigatinib) | More about Nivolumab | More about Retevmo (selpercatinib) | ||||||||||||||||
| Generic Status | ||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Nivolumab has an average rating of 5.0 out of 10 from a total of 114 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 51% reported a negative effect. |
Retevmo has an average rating of 10.0 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
|
See also: Alunbrig side effects in more detail. |
See also: nivolumab side effects in more detail. |
See also: Retevmo side effects in more detail. |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Alunbrig prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Retevmo prices |
||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
Opdivo |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
25 hours |
640.8 hours |
32 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 619 drugs are known to interact with Alunbrig:
|
A total of 20 drugs are known to interact with nivolumab:
|
A total of 603 drugs are known to interact with Retevmo:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
April 28, 2017 |
December 22, 2014 |
May 08, 2020 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.